PB-22, a recreational “designer drugs”, is a cannabimimetic agent, it is a full agonist of cannabinoid receptors. PB-22 has an EC50 of 5.1 nM for human CB1 receptors, and 37 nM for human CB2 receptors. PB-22 produces bradycardia and hypothermia in rats at doses of 0.3–3 mg/kg, suggesting potent cannabinoid-like activity. PB-22 was designated as a Schedule I controlled substance in the United States.

Methylone (3, 4-Methylenedioxy-N-methylcathinone), a β-keto analog of 3,4-methylenedioxy-N-methylamphetamine (MDMA) is a stimulant and psychoactive drug. Methylone is a popular drug of abuse that strongly increases the release of the three monoamines: dopamine, serotonin (5-HT) and norepinephrine. In addition, methylone inhibits plasma membrane catecholamine transporters but only weakly inhibit the vesicle transporter. In April 2013, methylone was listed in the Schedule 1 substance under the Controlled Substances Act.